According to Innoviva's latest financial reports the company has $0.17 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.29 B | 44.42% |
2021-12-31 | $0.20 B | -18.24% |
2020-12-31 | $0.24 B | -29.74% |
2019-12-31 | $0.35 B | 205.33% |
2018-12-31 | $0.11 B | -10.98% |
2017-12-31 | $0.12 B | -14.2% |
2016-12-31 | $0.15 B | -19.68% |
2015-12-31 | $0.18 B | -22.13% |
2014-12-31 | $0.24 B | -48.29% |
2013-12-31 | $0.46 B | 87.18% |
2012-12-31 | $0.24 B | 3.14% |
2011-12-31 | $0.24 B | -22.19% |
2010-12-31 | $0.30 B | 99.26% |
2009-12-31 | $0.15 B | -22.54% |
2008-12-31 | $0.20 B | 58.19% |
2007-12-31 | $0.12 B | -36.93% |
2006-12-31 | $0.20 B | 24.18% |
2005-12-31 | $0.16 B | -37.03% |
2004-12-31 | $0.25 B | 188.43% |
2003-12-31 | $89.15 M | -39.99% |
2002-12-31 | $0.14 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() OPKO Health
OPK | $0.13 B | -23.00% | ๐บ๐ธ USA |
![]() Onconova Therapeutics ONTX | $29.72 M | -83.48% | ๐บ๐ธ USA |